Sarepta Therapeutics | SRPT - Current Assets


Sarepta Therapeutics reported $2.54B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Capricor Therapeutics USD 322.94M 221.99M Dec/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Moderna USD 6.54B 54M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Tectonic Therapeutic USD 257.36M 15.88M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025